M. Ferrari
Houston Methodist Research Institute,
United States

Keywords: nanomedicine


Wait, not as in “post-mortem”…. Rather as in “post-genomics”…. As in: “Let’s use the knowledge gained in these last 20 years or so of research and development in nanomedicine and build the next generation of advances, where needed”. This is the focus of the talk, with an obvious bias toward the lines of investigation and clinical translation that we have been engaging in – simply because though they are probably not the smartest things around, these are still the ones we know best! So I will talk about a 25-year progression ( = string of failures, mostly) from photolithography-based silicon particles with drug reservoirs (1992) and the beginning of nanofluidics (1994ish) to multi-stage injectable drug delivery systems coupling micro- and nano-platforms (2008) with nanoporous silicon; transport oncophysics (2011) with its applications to immunotherapy (2015), to end with a new beginning: injectable nano-particle generators (iNPG), which in combination with polymeric doxorubicin (pDox) are actually able to completely cure metastatic forms of triple negative breast cancer in about 40% of the cases in preclinical models. It was time, no? Next challenge – move to clinic. Coming up.